ACLX
Price
$100.14
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
125 days until earnings call
RNA
Price
$49.97
Change
-$2.53 (-4.82%)
Updated
Nov 14 closing price
109 days until earnings call
Ad is loading...

ACLX vs RNA

Header iconACLX vs RNA Comparison
Open Charts ACLX vs RNABanner chart's image
Arcellx
Price$100.14
Change-$0.00 (-0.00%)
Volume$503.23K
CapitalizationN/A
Avidity Biosciences
Price$49.97
Change-$2.53 (-4.82%)
Volume$1.76M
CapitalizationN/A
ACLX vs RNA Comparison Chart
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ACLX vs. RNA commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Hold and RNA is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (ACLX: $100.14 vs. RNA: $52.50)
Brand notoriety: ACLX and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 89% vs. RNA: 248%
Market capitalization -- ACLX: $5.14B vs. RNA: $5.96B
ACLX [@Biotechnology] is valued at $5.14B. RNA’s [@Biotechnology] market capitalization is $5.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.77B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACLX and RNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 6 bullish TA indicator(s).

  • ACLX’s TA Score: 4 bullish, 4 bearish.
  • RNA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RNA is a better buy in the short-term than ACLX.

Price Growth

ACLX (@Biotechnology) experienced а +7.70% price change this week, while RNA (@Biotechnology) price change was +11.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +5.54%.

Reported Earning Dates

ACLX is expected to report earnings on Mar 20, 2025.

RNA is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($5.96B) has a higher market cap than ACLX($5.14B). RNA YTD gains are higher at: 480.111 vs. ACLX (80.432).
ACLXRNAACLX / RNA
Capitalization5.14B5.96B86%
EBITDAN/AN/A-
Gain YTD80.432480.11117%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
ACLXRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 8 days ago
0%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X90584.1640002628.351600
+2.99%
Bitcoin cryptocurrency
TSLA330.241.75
+0.53%
Tesla
AAPL225.120.89
+0.40%
Apple
SPY597.190.29
+0.05%
SPDR® S&P 500® ETF Trust
GME26.46-0.38
-1.42%
GameStop Corp

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
-0.34%
CRSP - ACLX
49%
Loosely correlated
-1.85%
BEAM - ACLX
48%
Loosely correlated
-1.57%
RCUS - ACLX
48%
Loosely correlated
-2.03%
MGTX - ACLX
46%
Loosely correlated
+5.71%
KYMR - ACLX
45%
Loosely correlated
-2.74%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+12.35%
DYN - RNA
48%
Loosely correlated
+16.37%
SWTX - RNA
41%
Loosely correlated
+4.86%
RXRX - RNA
40%
Loosely correlated
-3.43%
RCUS - RNA
39%
Loosely correlated
-2.03%
ACLX - RNA
39%
Loosely correlated
-0.34%
More